Commerce Bank Takes Position in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Commerce Bank purchased a new stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 15,000 shares of the company’s stock, valued at approximately $615,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Creative Financial Designs Inc. ADV bought a new stake in shares of GoodRx during the third quarter valued at about $55,000. AdvisorNet Financial Inc raised its stake in shares of GoodRx by 26.0% during the third quarter. AdvisorNet Financial Inc now owns 2,425 shares of the company’s stock valued at $99,000 after purchasing an additional 500 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in shares of GoodRx by 1,828.6% during the second quarter. PNC Financial Services Group Inc. now owns 2,700 shares of the company’s stock valued at $97,000 after purchasing an additional 2,560 shares in the last quarter. L & S Advisors Inc bought a new stake in shares of GoodRx during the third quarter valued at about $205,000. Finally, Oxler Private Wealth LLC bought a new stake in shares of GoodRx during the second quarter valued at about $216,000. 52.26% of the stock is owned by institutional investors.

GDRX has been the topic of a number of recent analyst reports. Morgan Stanley lifted their price objective on shares of GoodRx from $38.00 to $41.00 and gave the company an “equal weight” rating in a research note on Friday, December 17th. SVB Leerink dropped their price target on shares of GoodRx from $56.00 to $49.00 and set an “outperform” rating on the stock in a research report on Thursday, November 11th. Zacks Investment Research upgraded shares of GoodRx from a “sell” rating to a “hold” rating in a research report on Tuesday. Stephens began coverage on shares of GoodRx in a research report on Tuesday, December 21st. They issued an “overweight” rating and a $45.00 price target on the stock. Finally, The Goldman Sachs Group began coverage on shares of GoodRx in a research report on Friday, January 7th. They issued a “buy” rating and a $43.00 price target on the stock. Four investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $47.07.

In other GoodRx news, insider Andrew Slutsky sold 20,000 shares of GoodRx stock in a transaction dated Friday, October 22nd. The stock was sold at an average price of $46.74, for a total transaction of $934,800.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Trevor Bezdek sold 64,271 shares of the business’s stock in a transaction that occurred on Wednesday, December 22nd. The shares were sold at an average price of $35.19, for a total value of $2,261,696.49. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,393,259 shares of company stock worth $53,631,621. Company insiders own 1.43% of the company’s stock.

NASDAQ GDRX opened at $26.85 on Friday. The stock’s 50-day moving average price is $35.98 and its two-hundred day moving average price is $37.49. The company has a debt-to-equity ratio of 0.78, a quick ratio of 14.47 and a current ratio of 14.47. GoodRx Holdings, Inc. has a 1 year low of $25.07 and a 1 year high of $59.67.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings data on Wednesday, November 10th. The company reported $0.09 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.01 by $0.08. The firm had revenue of $195.10 million for the quarter, compared to the consensus estimate of $196.08 million. GoodRx had a negative return on equity of 31.61% and a negative net margin of 41.36%. During the same quarter in the previous year, the company earned ($0.25) EPS. As a group, equities analysts expect that GoodRx Holdings, Inc. will post 0.05 earnings per share for the current fiscal year.

GoodRx Company Profile

GoodRx Holdings, Inc, through its subsidiaries, provides information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.

Featured Article: What is the Moving Average Convergence Divergence (MACD) oscillator?

Want to see what other hedge funds are holding GDRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GoodRx Holdings, Inc. (NASDAQ:GDRX).

Institutional Ownership by Quarter for GoodRx (NASDAQ:GDRX)

Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.